article thumbnail

Should You Bother Targeting the Tech Blogs for Your PR Campaigns?

Both Sides of the Table

6 or 7 years ago when TechCrunch was at its peak market share (they are still strong but many more tech blogs have also popped up) there was a term for getting covered there called “the TechCrunch bounce.” It’s also important for recruiting, fund raising, business development and even company morale. Kind of obvious.

Blogging 309
article thumbnail

San Antonio Makes Pact to Commercialize Military, Academic Research

Xconomy

San Antonio — Life science groups, city officials, and research institutes in San Antonio are organizing an effort to commercialize more scientific developments coming out of the city’s military organizations. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Orbiting Organoids: Research in Space to Unveil New Neurodegeneration Insight

Xconomy

The National Stem Cell Foundation (NSCF) is funding the study, which is the result of a bi-coastal collaboration between the New York Stem Cell Foundation (NYSCF) Research Institute and Aspen Neuroscience, a San Diego startup developing personalized cell therapies for Parkinson’s disease.

article thumbnail

New COVID-19 Special Reports Explore Clinical Research During the Pandemic

Xconomy

. “ Decentralized Clinical Trials: The Call for a New Paradigm ” and “ Sustaining Clinical Research During the Crisis ” offer the latest trends and technologies companies can use to keep business running as smooth as possible.

article thumbnail

Charles River Labs Says It Will Close San Diego Research Facility

Xconomy

Contract research organization Charles River Labs is shutting down its San Diego-area operations, moving the work done there to one of its two Northern California sites. Charles River says it was involved with about 85 percent of the drugs. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

article thumbnail

Scripps Research, AbbVie Expand Drug Discovery Deal Beyond Cancer

Xconomy

The Scripps Research Institute and AbbVie have agreed to broaden an existing drug discovery agreement focused on cancer cell therapies to now encompass treatments for other kinds of disease. Financial terms of this latest agreement weren’t disclosed, but the deal expands the purview. Read more » Reprints | Share:

article thumbnail

Benchling Scores $14.5M to Grow Online Lab Notebook for Bio-Researchers

Xconomy

New immunotherapy approaches to cancer treatment, and the CRISPR technology for editing genetic material in cells, are among the most sophisticated research strategies scientists are using in their quest to defeat disease.